TESARO Inc (TSRO) Shares Bought by Bluestein R H & Co.

Bluestein R H & Co. raised its position in TESARO Inc (NASDAQ:TSRO) by 9.2% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 3,275 shares of the biopharmaceutical company’s stock after buying an additional 275 shares during the period. Bluestein R H & Co.’s holdings in TESARO were worth $504,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of TSRO. Interwest Venture Management Co. acquired a new position in TESARO during the fourth quarter worth approximately $271,838,000. Price T Rowe Associates Inc. MD boosted its position in TESARO by 16.2% in the third quarter. Price T Rowe Associates Inc. MD now owns 5,584,279 shares of the biopharmaceutical company’s stock worth $559,768,000 after buying an additional 776,709 shares in the last quarter. Perceptive Advisors LLC acquired a new position in TESARO during the fourth quarter worth approximately $92,521,000. Franklin Resources Inc. boosted its position in TESARO by 21.3% in the fourth quarter. Franklin Resources Inc. now owns 3,042,844 shares of the biopharmaceutical company’s stock worth $409,207,000 after buying an additional 534,851 shares in the last quarter. Finally, FMR LLC boosted its position in TESARO by 4.0% in the fourth quarter. FMR LLC now owns 8,011,003 shares of the biopharmaceutical company’s stock worth $1,077,320,000 after buying an additional 306,147 shares in the last quarter. 98.48% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for TESARO (NASDAQ:TSRO)

TESARO Inc (TSRO) traded down 0.64% during trading on Friday, hitting $138.78. The stock had a trading volume of 3,768,327 shares. TESARO Inc has a 12 month low of $36.71 and a 12 month high of $192.94. The company’s market cap is $7.48 billion. The company’s 50 day moving average is $145.17 and its 200-day moving average is $150.92.

TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.26) by $0.29. TESARO had a negative return on equity of 96.10% and a negative net margin of 4,449.23%. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. During the same quarter in the previous year, the business posted ($2.22) EPS. The business’s quarterly revenue was up 909.8% compared to the same quarter last year. On average, equities research analysts predict that TESARO Inc will post ($8.75) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “TESARO Inc (TSRO) Shares Bought by Bluestein R H & Co.” was first published by Mideast Time and is the property of of Mideast Time. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.mideasttime.com/tesaro-inc-tsro-shares-bought-by-bluestein-r-h-co/1767545.html.

A number of research analysts recently commented on TSRO shares. Zacks Investment Research cut TESARO from a “hold” rating to a “sell” rating in a report on Wednesday, March 22nd. Jefferies Group LLC lifted their price objective on TESARO from $80.00 to $124.00 and gave the stock a “hold” rating in a research note on Monday, March 27th. Cowen and Company reduced their price objective on TESARO from $155.00 to $145.00 and set a “market perform” rating on the stock in a research note on Wednesday, March 15th. Piper Jaffray Companies began coverage on TESARO in a research note on Wednesday, April 12th. They issued an “overweight” rating and a $180.00 price objective on the stock. Finally, Vetr raised TESARO from a “buy” rating to a “strong-buy” rating and set a $178.33 price objective on the stock in a research note on Monday, March 27th. Nine investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $174.42.

In related news, VP Edward C. English sold 8,500 shares of TESARO stock in a transaction that occurred on Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the transaction, the vice president now owns 5,396 shares in the company, valued at $748,155.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Martin H. Jr. Huber sold 829 shares of TESARO stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $153.02, for a total value of $126,853.58. Following the transaction, the senior vice president now owns 6,522 shares in the company, valued at approximately $997,996.44. The disclosure for this sale can be found here. Company insiders own 40.50% of the company’s stock.

TESARO Company Profile

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:TSRO”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO Inc (NASDAQ:TSRO).

Receive News & Ratings for TESARO Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.